Moderna (MRNA) has been struggling to shake one label for years: Covid winner.
That label helped to make the company famous, but it also became a problem for the stock when pandemic demand dropped and investors questioned whether Moderna could develop a stable business beyond one historic product cycle
Now the corporation may have a fresh response. The Food and Drug Administration (FDA) is getting ready to evaluate Moderna’s messenger RNA-based flu shot, MFLUSIVA, Fierce Biotech reported, and the landscape appears more positive than investors might have expected. The problem is larger than a single seasonal vaccine.
For Moderna investors, the question is whether the company’s mRNA platform can be a recurring commercial engine or just another pandemic-era success tale. Moderna CEO Stéphane Bancel said the company is “excited to return to sales growth in 2026.” Moderna needs proof that its vaccine platform still matters The bull case for Moderna has always been a straightforward promise: mRNA can be utilized to make medicines and vaccines faster than existing platforms. That promise worked magnificently during the Covid pandemic.